tesamorelin lipodystrophy: Frequently asked questions

Continue through week 20–24 before evaluating efficacy. Individual response variability means some patients don't show measurable VAT reduction until week 16–18. Ensure injection technique is correct (subcutaneous, not intramuscular), reconstitution followed manufacturer guidelines (bacteriostatic water, gentle mixing without shaking), and storage maintained 2–8°C throughout. If serum IGF-1 remains below 150 ng/mL at week 12, pituitary responsiveness may be impaired. Discuss GH stimulation testing with your prescribing physician.

Elevated fasting glucose or HbA1c occurs in 6–8% of tesamorelin users, likely due to GH's counter-regulatory effect on insulin signaling. If fasting glucose rises above 126 mg/dL or HbA1c increases by more than 0.5%, dietary carbohydrate restriction and timing adjustments can mitigate the effect. In cases where glucose dysregulation persists, co-administration of metformin (500–1000mg daily) has been used off-label to improve insulin sensitivity.

This is the expected trajectory. Tesamorelin's maximum effect occurs between months 6–9 for most patients, with minimal additional fat loss beyond that point. The plateau doesn't indicate tolerance or receptor downregulation; it reflects the physiologic limit of GH-mediated lipolysis in visceral depots. Continuing daily dosing maintains achieved VAT reduction; stopping triggers reaccumulation. Some practitioners adjust to 5-days-on/2-days-off schedules after month 9 to reduce injection frequency while preserving most metabolic benefit.

Missed doses during the ramp-up phase delay the timeline but don't negate progress entirely. Tesamorelin's half-life is approximately 26–38 minutes, meaning each dose effect is transient. Missing 3–4 consecutive days resets IGF-1 levels back toward baseline, requiring 7–10 days to re-establish therapeutic range once dosing resumes. If you miss more than 5 days during weeks 1–8, consider extending your evaluation window to week 28–30 rather than week 26.

Administer the missed dose as soon as you remember, provided it is still evening and you have not eaten within the past 90 minutes. If more than 12 hours have passed or you have already eaten dinner, skip the missed dose and resume your regular schedule—do not double-dose. Missing 1–2 doses in a 26-week treatment cycle has minimal impact, but missing doses frequently can reduce efficacy by 20–30%.

Arthralgia occurs in approximately 13% of patients and is typically related to fluid retention mediated by elevated IGF-1 levels. The pain usually peaks during weeks 4–8 and resolves by week 12. If joint pain is severe, reducing the dose to 1mg daily for 2–4 weeks before escalating back to 2mg can allow gradual tolerance development. Persistent arthralgia beyond 16 weeks warrants IGF-1 level testing and consultation with your prescribing physician.

Rotate injection sites systematically. Abdomen, thighs, upper arms. To prevent lipohypertrophy or tissue induration from repeated trauma to the same area. Injection site reactions (erythema, pruritus, mild swelling) occur in 15–25% of users but rarely require discontinuation. Let reconstituted solution reach room temperature before injecting (15–20 minutes out of refrigeration) to reduce discomfort. Persistent nodules or hardened tissue at injection sites suggest improper technique. Subcutaneous injections should be delivered at a 45–90° angle using a 27–30 gauge needle, not intramuscularly.

Administer the dose as soon as you remember if fewer than 12 hours have passed since your scheduled time. If more than 12 hours have passed, skip the missed dose entirely and resume your regular schedule the following morning. Do not double-dose to compensate. Missing a single injection creates a brief interruption in pulsatile GH stimulation but does not negate prior progress. Missing three or more consecutive doses may require restarting the titration process depending on how long you've been on therapy; consult your prescribing physician before resuming.

Discard the vial immediately and do not inject. Cloudiness, particulates, or discolouration indicate protein aggregation or contamination. Neither is reversible, and injecting degraded peptide provides no therapeutic benefit while introducing infection risk. Proper reconstitution produces a clear, colourless solution. If cloudiness appears consistently across multiple vials from the same batch, contact the supplier. This may indicate a manufacturing or storage issue.

Transient glucose elevation occurs in 8–10% of patients and typically peaks between weeks 4–8 before declining as visceral fat reduction improves insulin sensitivity. If fasting glucose remains below 126 mg/dL and HbA1c increases by less than 0.5%, continue therapy under close monitoring. If fasting glucose exceeds 126 mg/dL on two consecutive measurements or HbA1c rises by more than 0.5%, discontinuation may be necessary. Never adjust diabetes medications independently. Glucose changes require prescriber oversight.